CRISPR_News
A
Biotech startup, Tune Therapeutics, uses its CRISPR-based TEMPO platform to target epigenetic marks, achieving a 56% reduction in LDL-C cholesterol levels in monkeys without permanently altering DNA - an encouraging stride toward safer gene editing.🧬https://www.freethink.com/...
10:30 PM - May 30, 2023
Avatar Avatar Avatar
0
0
7

 

{{ notificationModalContent }} {{ promptModalMessage }}